Dipharma contributes to the U.S. Life Sciences 2024 publication
Panel discussion on Custom synthesis & Contract manufacturing
Dipharma Francis Srl – Share capital: € 8.400.000 fully paid-up
R.E.A. Milan: 1 3 3 3 3 8 6 – VAT IT 0 9 9 7 1 0 8 0 1 5 6
Panel discussion on Custom synthesis & Contract manufacturing
Dipharma Francis Srl – Share capital: € 8.400.000 fully paid-up
R.E.A. Milan: 1 3 3 3 3 8 6 – VAT IT 0 9 9 7 1 0 8 0 1 5 6